MedicaidJuly 28, 2023
Clinical Criteria updates - March 2023
On August 19, 2022, and March 23, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem Blue Cross and Blue Shield Medicaid (Anthem). These policies were developed, revised, or reviewed to support clinical coding edits.
Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email.
Please see the explanation/definition for each category of Clinical Criteria below:
- New: Newly published criteria
- Revised: Addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive.
Please share this notice with other providers in your practice and office staff.
Please note:
- The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Clinical Criteria number | Clinical Criteria title | New or revised |
September 10, 2023 | *CC-0235 | Revcovi (elapegademase-lvlr) | New |
September 10, 2023 | *CC-0236 | Signifor LAR (pasireotide) | New |
September 10, 2023 | CC-0125 | Opdivo (nivolumab) | Revised |
September 10, 2023 | CC-0072 | Vascular Endothelial Growth Factor (VEGF) Inhibitors | Revised |
September 10, 2023 | CC-0038 | Human Parathyroid Hormone Agents | Revised |
September 10, 2023 | CC-0066 | Monoclonal Antibodies to Interleukin-6 | Revised |
September 10, 2023 | *CC-0197 | Jemperli (dostarlimab-gxly) | Revised |
September 10, 2023 | *CC-0119 | Yervoy (ipilimumab) | Revised |
September 10, 2023 | CC-0092 | Adcetris (brentuximab vedotin) | Revised |
September 10, 2023 | *CC-0065 | Hemophilia A and von Willebrand Disease | Revised |
September 10, 2023 | *CC-0034 | Agents for Hereditary Angioedema | Revised |
September 10, 2023 | CC-0061 | GnRH Analogs for the Treatment of Non-Oncologic Indications | Revised |
September 10, 2023 | CC-0008 | Subcutaneous Hormonal Implants | Revised |
September 10, 2023 | CC-0026 | Testosterone, Injectable | Revised |
KYBCBS-CD-027396-23-CPN26410
PUBLICATIONS: September 2023 Provider Newsletter
To view this article online:
Visit https://providernews.anthem.com/kentucky/articles/clinical-criteria-updates-march-2023-20-14809
Or scan this QR code with your phone